Nabriva Therapeutics (NBRVF) Price & Analysis

1,011 Followers

NBRVF Stock Chart & Stats

$0.01

$0.00(0.00%)

At close: Jan 02 4:00 PM EST

$0.01

$0.00(0.00%)

Day’s Range― - ―

52-Week Range$0.01 - $0.01

Previous CloseN/A

Volume415.00

Average Volume (3M)591.00

Market Cap

$323.00

Enterprise Value$4.21

Total Cash (Recent Filing)$2.18M

Total Debt (Recent Filing)$540.00K

Price to Earnings (P/E)―

Beta51.97

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding3,230,837

10 Day Avg. Volume591

30 Day Avg. Volume591

Financial Highlights & Ratios

PEG Ratio<0.01

Price to Book (P/B)0.77

Price to Sales (P/S)0.07

P/FCF Ratio-0.07

Enterprise Value/Market Cap0.01

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit>-0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

NBRVF FAQ

What was Nabriva Therapeutics’s price range in the past 12 months?

Nabriva Therapeutics lowest stock price was $0.01 and its highest was $0.01 in the past 12 months.

What is Nabriva Therapeutics’s market cap?

Nabriva Therapeutics’s market cap is $323.00.

When is Nabriva Therapeutics’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Nabriva Therapeutics’s earnings last quarter?

Currently, no data Available

Is Nabriva Therapeutics overvalued?

According to Wall Street analysts Nabriva Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Nabriva Therapeutics pay dividends?

Nabriva Therapeutics does not currently pay dividends.

What is Nabriva Therapeutics’s EPS estimate?

Nabriva Therapeutics’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Nabriva Therapeutics have?

Nabriva Therapeutics has 3,230,837 shares outstanding.

What happened to Nabriva Therapeutics’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Nabriva Therapeutics?

Currently, no hedge funds are holding shares in NBRVF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Nabriva Therapeutics

Nabriva Therapeutics plc is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative anti-infective medicines for managing serious infections. Its current portfolio includes SIVEXTRO, an oxazolidinone-class antibacterial utilized for acute bacterial skin and skin structure infections (ABSSSI). Another key product is XENLETA, a semi-synthetic pleuromutilin antibiotic available for both oral and intravenous administration. XENLETA is also currently advancing through Phase I clinical trials for additional indications, such as pediatric infections, sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. Moreover, the company is progressing CONTEPO, an epoxide antibiotic designed to address complicated urinary tract infections, which is concurrently in Phase I clinical evaluation for peri-operative prophylaxis. Founded in 2005 as Nabriva Therapeutics Forschungs GmbH, the company rebranded to Nabriva Therapeutics plc in 2007 and is headquartered in Dublin, Ireland.